AlphaQuest LLC Buys New Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

AlphaQuest LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,924 shares of the biotechnology company’s stock, valued at approximately $84,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ADMA. PNC Financial Services Group Inc. increased its position in shares of ADMA Biologics by 13.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 18,772 shares of the biotechnology company’s stock worth $322,000 after acquiring an additional 2,279 shares in the last quarter. E Fund Management Co. Ltd. grew its holdings in ADMA Biologics by 45.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 36,469 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 11,351 shares in the last quarter. Inceptionr LLC purchased a new stake in ADMA Biologics during the 4th quarter worth $452,000. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics during the fourth quarter worth about $19,076,000. Finally, First Business Financial Services Inc. acquired a new position in shares of ADMA Biologics in the fourth quarter worth about $343,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $18.71 on Wednesday. The firm’s 50 day moving average is $16.67 and its two-hundred day moving average is $17.98. The firm has a market capitalization of $4.42 billion, a P/E ratio of 66.82 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.